GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rang in aandelen
#3667
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aandeelprijs
$27.17
Marktkapitalisatie
$4.60B
Verandering (1 dag)
-1.33%
Verandering (1 jaar)
-13.30%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categorie
Healthcare
P/B-ratio voor GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
P/B-ratio op October 2026 TTM: 18.70
Volgens de meest recente financiële rapporten en aandelenkoers van GlaxoSmithKline Pharmaceuticals Limited is de huidige P/B-ratio (TTM) 18.70. Eind 2024 had het bedrijf een P/B-ratio van 18.93.
P/B-ratiohistoriek voor GlaxoSmithKline Pharmaceuticals Limited van 2004 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 18.70 | -23.00% |
| 2025 | 24.29 | 28.30% |
| 2024 | 18.93 | 46.87% |
| 2023 | 12.89 | 21.54% |
| 2022 | 10.60 | -35.77% |
| 2021 | 16.51 | 41.12% |
| 2020 | 11.70 | 13.72% |
| 2019 | 10.29 | 18.79% |
| 2018 | 8.66 | -25.23% |
| 2017 | 11.58 | -39.20% |
| 2016 | 19.05 | 60.47% |
| 2015 | 11.87 | -7.01% |
| 2013 | 12.77 | 39.51% |
| 2012 | 9.15 | 7.51% |
| 2011 | 8.51 | -16.10% |
| 2010 | 10.15 | 32.71% |
| 2009 | 7.64 | 23.58% |
| 2008 | 6.19 | -1.82% |
| 2007 | 6.30 | -22.76% |
| 2006 | 8.16 | -19.22% |
| 2005 | 10.10 | 38.74% |
| 2004 | 7.28 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 31.9092 | 70.60% |
US
|
|
| 7.3138 | -60.90% |
US
|
|
| -84.6033 | -552.32% |
US
|
|
| 8.6873 | -53.56% |
US
|
|
| 8.4776 | -54.68% |
CH
|
